Moxonidin in combined therapy of metabolic syndrome
https://doi.org/10.18705/1607-419X-2007-13-4-246-249
Abstract
The paper presents the results of 24-weeks follow-up and treatment patients with metabolic syndrome.
It shows antihypertensive effect of imidazoline-receptor agonist moxonidine and hypolipidemic effect of micronized fenofibrate in patients with metabolic syndrome. The combination demonstrate synergic action on carbohydrate and uric acid metabolism. Thus, it can significantly decrease the level of cardio-vascular risk (SCORE) in patients with metabolic syndrome.
It shows antihypertensive effect of imidazoline-receptor agonist moxonidine and hypolipidemic effect of micronized fenofibrate in patients with metabolic syndrome. The combination demonstrate synergic action on carbohydrate and uric acid metabolism. Thus, it can significantly decrease the level of cardio-vascular risk (SCORE) in patients with metabolic syndrome.
About the Authors
V. I. Podzolkov
ГОУ ВПО Московская медицинская академия им. И.М. Сеченова Росздрава
Russian Federation
Russian Federation
E. A. Gladysheva
ГОУ ВПО Московская медицинская академия им. И.М. Сеченова Росздрава
Russian Federation
Russian Federation
A. E. Bragina
ГОУ ВПО Московская медицинская академия им. И.М. Сеченова Росздрава
Russian Federation
Russian Federation
References
1. Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Journal of Hypertension 2007, 25:1105-1187
2.
3. Chobaniam AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
4.
5. Глезер М.Г., Бойко Н.В., Абильдинова А.Ж. и соавт. Факторы риска у московской популяции больных с артериальной гипертонией // Российский кардиологический журнал. 2002. №6. С.23-26
6.
7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) //JAMA. 2001.V.285. P.2486-2497.
8.
9. Third Joint Task Force of European and other Societies of Cardiovascular disease. Prevention in Clinical Practice. European Guidelines on Cardiovascular disease prevention in clinical practice //European Heart Journal. 2003. V.24. P.1601-1610.
10.
11. Подзолков В.И., Брагина А.Е., Маколкин В.И. Патогенетическая роль моксонидина при лечении артериальной гипертензии у женщин в перименопаузе. Кардиология, 2002, №11,С.32-35.
12.
13. Перова Н.В., Олферьев A.M., Мамедов М.Н. и др. Моксонидин (Физиотенз) корригирует комплекс факторов риска атеросклеротических заболеваний при метаболическом синдроме//Клин фармакол Тер. 2001.10(3). С 22-25.
14.
15. Haenni A, Lithell H. Moxonidin improves insulin sensivity in insulin-resistance hypertensives//J Hypertens. 1999.17(Suppl.3). P. S29-35
16.
17. Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом (результаты исследования ALMAZ) // Consilium Medicum. Приложение Системные гипертензии. 2006. №2. С.14-18.
18.
19. Т.Ю.Демидова, А.С.Аметов, Л.В.Смагина Моксонидин в коррекции метаболических нарушений и эндотелальной дисфункции у больных сахарным диабетом типа 2, ассоциированным с артериальной гипертензией //Артериальная гипертензия,2004. Т. 10. №2. С. 104-109.
20.
21. Sanjuliani AF, Genelhu-Fagunde V, Barroso SG et al. Effect of imidazoline agonist on sympathetic activity and components of the insulin resistance syndrome in obese hypertensive Brasilian patients //J Hypertens 2002. V.20. S206 [abstract
22.
Review
For citations:
Podzolkov V.I., Gladysheva E.A., Bragina A.E. Moxonidin in combined therapy of metabolic syndrome. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(4):246-249. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-4-246-249
Views:
920
Email this article 